Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The target population typically has better health than participants in health research studies, such as cancer screening trials (the "healthy volunteer" effect).
Read Full NewsDESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.
A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?
High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.
Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.
1.
Guidelines for cervical cancer screening and the risk of preterm birth in young women.
2.
Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?
3.
A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.
4.
Trump slashed US cancer research by 31 percent: Senate report
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
2.
Managing Acute Respiratory Failure in Hematological Malignancies
3.
Debunking Myths About Systemic Mastocytosis: Separating Fact from Fiction
4.
Unveiling the Hidden Mechanisms of Hemolytic Reactions
5.
Oncology Treatment: Innovations, Education, and Clinical Practice Insights
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Evidence-Based Oncology
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
5.
Navigating the Complexities of Ph Negative ALL - Part XIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge